Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Portfolio Pulse from Benzinga Newsdesk
Cardiol Therapeutics Inc. (NASDAQ:CRDL) reported positive topline data from its Phase II MAvERIC-Pilot study, showing that its drug CardiolRx™ significantly reduced pericarditis pain and inflammation in patients. 89% of patients have continued into the extension phase of the study.
June 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiol Therapeutics Inc. reported positive results from its Phase II MAvERIC-Pilot study, showing that CardiolRx™ significantly reduced pericarditis pain and inflammation. This is likely to boost investor confidence and positively impact the stock price in the short term.
The positive clinical trial results for CardiolRx™ are a significant milestone for Cardiol Therapeutics, likely to enhance investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100